Semax
ACTH(4-7)PGP (Methionyl-Glutamyl-Histidyl-Phenylalanyl-Prolyl-Glycyl-Proline)
Access and compounding status raise extra safety and legal questions.
A synthetic peptide developed and used clinically in Russia as a nasal spray for stroke recovery and improving mental sharpness. It boosts natural brain growth factors and has brain-protective properties, but is not approved by the US FDA or European regulators.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
No published Phase I/II trial or regulatory document with tabulated adverse-event frequencies (percentages) or formal severity grading was identified. The absence of quantitative incidence tables is itself noted in multiple literature reviews. No reproducible signals of systemic organ toxicity, anaphylaxis, or other consistent serious adverse events (SAEs) were identified. No tolerance, dependence, or withdrawal syndromes have been reported. No carcinogenicity signals found. Anecdotal reports suggest higher doses may increase overstimulation and insomnia risk. Long-term human safety data are limited.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-13]